Canada - English - Health Canada

guerbet - patent blue sodium - solution - 50mg - patent blue sodium 50mg - other diagnostic agents

United States - English - NLM (National Library of Medicine)

prodibio sas - gentian violet (unii: j4z741d6o5) (gentian violet cation - unii:3gvj31t6yy), malachite green oxalate (unii: gy1h9o33vu) (malachite green - unii:12058m7oro), acriflavine hydrochloride (unii: 1s73vw819c) (acriflavine - unii:1t3a50395t), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh) - gentian violet 0.5 mg in 1 ml - invertebrates such as snails and shrimps cannot withstand spots & velvets fresh, and must be removed from the aquarium before beginning the treatment. some filiform plants can be damaged by the treatment. the simultaneous use of softened water may decrease the effectiveness of treatment. do not use with another treatment. dispose od drugs not entirely used up at the respective collecting points disposal advice: after use, vials must be thrown in recyclable glass rubbish

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - tamoxifen citrate - oral tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - tamoxifen citrate - oral tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - tamoxifen citrate - oral tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

orion pharma (uk - toremifene citrate - tablet - 60mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

arrow generics ltd - tamoxifen citrate - oral tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - tamoxifen citrate - oral tablet - 20mg

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - tamoxifen citrate, quantity: 30.4 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; lactose monohydrate; gelatin; titanium dioxide; maize starch; macrogol 300; hypromellose; magnesium stearate - treatment of breast cancer nolvadex-d is indicated for the treatment of breast cancer. primary reduction of breast cancer risk nolvadex-d is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - tamoxifen citrate - oral tablet - 20mg